financetom
Business
financetom
/
Business
/
American Healthcare REIT lifts FY25 same-store NOI growth guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
American Healthcare REIT lifts FY25 same-store NOI growth guidance
Aug 7, 2025 2:50 PM

Overview

* American Healthcare REIT ( AHR ) Q2 Same-Store NOI grows 13.9% yr/yr

* Company increases full-year 2025 guidance for Same-Store NOI and NFFO

* Co acquires new SHOP asset for $65 mln, enhancing portfolio growth

Outlook

* Company raises full-year Same-Store NOI growth guidance to 11%-14%

* American Healthcare REIT ( AHR ) increases NFFO guidance to $1.64-$1.68 per share

* Company anticipates higher occupancy through summer selling season

Result Drivers

* OCCUPANCY GAINS - Co attributes Same-Store NOI growth to steady occupancy gains in ISHC and SHOP segments

* EXPENSE MANAGEMENT - Proactive expense management contributed to improved operating results, per COO Gabe Willhite

* ACQUISITIONS - Acquisition of new SHOP asset for $65 mln and strategic capital allocation activities enhanced portfolio growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net $10.08

Income mln

Q2 $10.81

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialized reits peer group is "buy"

* Wall Street's median 12-month price target for American Healthcare REIT Inc ( AHR ) is $40.00, about 0.9% above its August 6 closing price of $39.65

* The stock recently traded at 74 times the next 12-month earnings vs. a P/E of 76 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Oct 17, 2025
Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain. Boston Scientific (...
Form 8.3 - Unite Group
Form 8.3 - Unite Group
Oct 17, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: CCLA Investment Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
SLB beats estimates for third-quarter profit on strong North America demand
SLB beats estimates for third-quarter profit on strong North America demand
Oct 17, 2025
(Reuters) -SLB beat Wall Street estimates for third-quarter profit on Friday, helped by strong demand for its oilfield equipment and services in North America. The company reported an adjusted profit of 69 cents per share for the quarter ended September 30, compared with analysts' estimate of 66 cents, according to data compiled by LSEG. Quarterly revenue from its North America...
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
Oct 17, 2025
CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ( XRTX ) (“XORTX” or the “Company”) , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a binding term sheet (the “Term Sheet”) to acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems...
Copyright 2023-2026 - www.financetom.com All Rights Reserved